Light Chain (AL) Amyloidosis Clinical Trial
Official title:
Venetoclax Combined With Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis Patients With Translocation (11;14): A Multicenter Phase 2 Study
Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic response in AL patients with favorable safety profile. As an oral agent with encouraging data, it is worth to prospectively evaluate the efficacy and safety of venetoclax in untreated AL amyloidosis patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05692908 -
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis
|
Phase 1 | |
| Withdrawn |
NCT04943302 -
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
|
Phase 2 | |
| Not yet recruiting |
NCT06097832 -
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
|
Phase 1 | |
| Recruiting |
NCT05486481 -
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06376214 -
Daratumumab for Patients With Light Chain Amyloidosis
|
N/A | |
| Recruiting |
NCT04973137 -
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
|
Phase 3 | |
| Completed |
NCT02015312 -
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
|
Phase 2 | |
| Recruiting |
NCT04316442 -
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
|
Phase 1/Phase 2 |